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D URING the period 5/9/81 to 5/9/82. 27 
consecutive liver transplantations were 
performed on 23 pediatric patients. Ages 
ranged from 7.5 months to 18 years. There 
were II males and 12 females. Four patients 
were adolescents (12-18 years). 6 patients 
were school age (5-10 years). and 13 were 
infants to preschools (7.5 months-4.5 years). 
Follow-up time ranged from 3.5 months to 
15.5 months. Survival stands at 70% (16/23). 
while 61 % (14/23) can be described as in 
excellent condition. 
Orthotopic liver transplantation (OL T) 
has. since its inception, I been a procedure with 
high mortality and morbidity. Steady im-
provement in survival statistics have. however. 
occurred during the 20-year history of the 
procedure. Improvements in surgical tech-
nique. patient selection. and immunosuppres-
sion have moved OL T into the realm of practi-
cal therapeutics. 
Pediatric OL T. while always enjoying 
slightly better survival statistics than its adult 
counterpart.2 has had added morbidity with-
out correlate in the nonpedialric population. 
The profound effect of high doses of steroids 
on the child, which leads not only to growth 
failure but also to Cushingoid changes. has 
prompted ~ome to question the use of trans-
plantation in children 3 at all. 
We report improved survival statistics for 
pediatric OL T under cyclosporin-A (CyA) 
and low-dose steroids. as well as preliminary 
data suggesting normal growth velocity post-
transplantation in these patients. 
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© 1983 by Grune & Stratton, fncK~ 
MM41-1P4R/UP/1RM/~P11AlfKll/l 
1292 
MATERIALS AND METHODS 
Patient Selection 
All the patients listed in Table I represent I-year 
experience with liver transplantation dating from 5/9/81 
to 5/9/82. Nineteen patients received I graft and while 3 
patients had 2 grafts, and I patient had a total of 3 
grafts. 
Biliary atresia with a failed allempt at restoration of 
bile drainage by portoenterostomy represented the most 
frequent indication for liver transplantation in children. 
Following biliary atresia. are a variety of inborn errors of 
metabolism (alpha-I-antitrypsin [A,A T] deficiency be-
ing by far the most frequent of the inborn errors), biliary 
hypoplasia, chronic active hepatitis. neonatal hepatitis. 
secondary biliary cirrhosis. Jnd familial intrahepatic cho-
lestasis. 
Patients who were transplanted were initially placed on 
a transplant candidacy list follOWing an in-hospital medi-
cal evaluation. The evaluation was undertaken to (I) 
verify acceptable pre transplantation anatomy (generally 
requiring demonstration of a patent extrahepatic portal 
vein), (2) review the patient's diagnosis (accomplished by 
a review of medical records, biopsy slides. and occasion-
ally other further testing), and (3) an attempt at gaugeing 
the medical urgency of transplantation. 
Transplantation recipients were chosen from the candi-
dacy list based on the size of the available organ. the blood 
type of the organ donor, and the type and severity of the 
liver disease of the recipient. Selection was made indepen-
dent of H LA typing or patient donor crossmatch data. 
While size matching was rather strictly adhered to. one of 
the patients in the series was an ABO mismatch with the 
donor. Patients who received grafts either suffered from a 
disease entity whose course is predictably and rapidly 
downhill (i.e .• biliary atresia), had multifocal neoplasia or 
neoplasia with cirrhosis complicating metabolic liver dis-
ease. or had reached end-stage"s with a liver disease 
whose course is less predictable (i.e .• A,A T deficiency).' 
One patient in the series did not fall into any of the 3 
aforementioned categories and received a transplant. 
That patient was an A I AT-deficient child who had devel-
oped social invalidism' from associated hepatogenic cya-
nosis.' 
Surgery 
Hepatectomy of the donor organ was performed at the 
hospital of the donor's death. The organ graft was 
preserved in Collin's solution during transport.' The 
method of transplantation has been described previous-
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Table 1. Indications for Liver Transplantation in Children 
Number of Follow-up Time 
(Months' Disease 
Biliary atresia 
Inborn error /totals) 
Alpha-i-antitrYPsin 
Wilson's 
Tyrosinosis with hepatoma 
GSO-I 
Sea Blue Histiocytes 
with hepatoma 
Biliary hypoplasia 
CAH 
Secondary biliarv 
cirrhoSIS 
Neonatal hepatnis 
Familial intrahepat,c 
cholestilSls 
Patients 
7 
B 
4 
1 
3 
2 
ly.'O Cold ischemia time depended to a large extent on the 
distance to the donor hospital. but in all instances was less 
than) 2 hr. Prophylactic antibiotics were initiated at the 
time of surgery and continued for 4 days. Further antibi-
otic use was dependent on the patient's clinical course. 
Immune Suppression 
The immunosuppressive regimen used has recently 
been described in detail" Essentially. it consisted of oral 
CyA initiated 4-6 hr before surgery. or its IV equivalent 
if 4 hr lead time was not possible. and steroids begun 
intraoperatively and tapered over the following 5 days 
from a high dose to a low dose (5-10 mg prednisone) level. 
Both CyA and steroid therapy were individualized from 
patient to patient dependent on the patient's clinical 
status and/or the intervention of rejection episodes. 
Rejection episodes were treated with bolus of IV Solucor-
tef and/or CyA dosing changes, and/or reinstitulion of 
R~day prednisone bursts. which begin with high doses of 
steroids and taper over 4 days to low dose of steroids. 
RESULTS 
Table 2 lists the follow-up data for the 
transplanted patients. Sex and age did not 
affect outcome. Though historically, patients 
with biliary atresia have had poorer outcome 
than pediatric patients transplanted for other 
reasons, disease did not impact on outcome in 
this series. Finally, clinical condition (defined 
as grave in hospital-bound patients, fair in 
those patients living at home under medical 
management of liver decompensation, and 
good in patients living at home without any 
Survivors 
5 
6 
2 
o 
3.5 to 15.5 
5.0 to 14.0 
5.0 to 14.0 
11.0 
9.0 
6.0 
5.0 
8.0 
4.0 to 5.0 
9.0 
13.0 
liver decompensation) did not impact on post-
operative survival. 
Four of the patients had preexisting cyto-
toxic antibodies to the donor. Table 3 reviews 
these patients. Antibodies were either ABO 
isoagglutinins or T-warm cytotoxic antibod-
ies. The latter antibody kills all of the donor 
lymphocytes in vitro. Though the numbers are 
small, the data support a real increased risk in 
these patients. However, it can also be seen 
from the case material that violating the 
immunologic barrier presented by preexisting 
antibodies does not preclude the possiblity of 
excellent outcome. 
Follow-up 
Seventy percent (16/23 of the transplanted 
patients) are survivors, while 61% (14/23 
patients) are in excellent condition. Two 
patients (OT 214, 229) are suffering from 
chronic rejection. 
Figure I is the growth curve on one of the 
transplanted patients. It can be seen that 
growth velocity following transplantation has 
been normal in this patient. This patient's 
growth curve is representative of other 
patients also transplanted under CyA and 
low-dose steroids l2 who have I-year follow-up 
time. 
Five of the patients in this series have 
follow-ups greater than I year. Two of the 5 
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Table 2. Outcome of 23 Consecutive Pediatric Liver Transplantations 
Age at Immune SlJppreS!$lon 
lnltlat CondittOn Follow-up 
Pat...,. Transplant at Time of Present Time evA 
OTNo. {Year,1 Sex DiagnosiS Transplant Status ,Monthsl m.g Pred/dav mg/kg/dav BIlirubin 
189 22/3 M Bllaary aUftSl8 sIP Kasal Good E .... cellent 15.5 ' 1 
190 B"'-v atresl. sIp Kasal Fair ElCceUent 15 15 
191 2 1/6 M Biliary atres&8 sip Kasal Good Excellent 15 10 
192 101/2 M AIAT Cntlcal Excellent. persistent hVperw 14.5 
tension 
193 101/6 Famthat c~estapls F •• Excellent I. 
201 • 1/2 M A,Ar F •• Died with biliary leak and 1 month until death 
abscess 
202 101/2 M Wilson's disease Critical Excellent 11 ' 1 
203 18 M A1AT with hepatogenic F •• Dted with cerebral hemor- 3 months until death 
cyanoSiS rhage after second 
transplant 
205 2/3 NeonatlN hepatitis CntlCal Excellent 16.5 
206 2213 TyrOSInemia with hepatoma Good Excellent 16 
213 M Bili.-y atreSIa sip Kasal Good Exce4lent 
21' 2213 M Biliary hypoplaSia Cntlcal Fair, ongomg chroniC reteC- 10 16 17 
lOon 
216 15/6 Bib..., atresia sip Kasal Good Daed 2 0 to liver failure of 3 months unCl1 death 
rejeCtion 
218 17 GSO I with adenomata Good Excellent 10 12.5 '. I 
220 82/3 ChoMtdochal cySt 2" biliary Cntlcal DIed at 2nd attempt at 
ClIThosis grahlng. fatted 2" pOftal 
vem obstruction 
222 Se ... Slue histiOCytoSis Good Excellent 15 12 
226 A1AT entlCal Excellent 3 1/2 12 
228 3 1/3 M 8,I..-v hypoplasia F •• Died 2" to sepSIS 1/2 month until death 
229 16 M C~omc active hap.lltls Cntlcal Cflttcal With chronic rel8C- 3 1/2 30 30 19 
lOon 
232 62/3 Biliary auesla Good Dutd With IschemiC liver fn~ 1/3 month until death 
,""I 
233 I 2/3 Biliary hypoplaSia Good Died at surgery, found to Immedtate postopet'altve 12 ._1 
have SVC absence death 
236 8iliaty aUes.a sIp Kaul Fa. Excellent 10 17 , 1 
237 16 M ChrontC actIve "'-'atltlS CrttlCcd Excellent 20 20 
patients were school age and 3 were preschool-
ers. Only I patient had significantly delayed 
development (OT 189) at the time of trans-
plantation. That patient had required monthly 
hospitalizations for G I bleeding and fluid and 
electrolyte imbalance from age 1.5 years until 
transplantation at age 4 years. The remaining 
toddlers were transplanted early enough in the 
course of their diseases that severe morbidity 
had not occurred, while the school-age chil-
dren had only had decompensated disease in 
the months prior to transplantation. Table 3. Outcome of Patients With Preexisting 
Cytotoxic Antibodies 
Patient 
OT 190 
OT 193 
OT229 
OT 232 
Antibody 
Twarm 
ABO isoagglutinIn 
Twarm 
Twarm 
Outcome 
Mild persistent rejec-
tion, controlled after 
3 months of weekly 
steroid bolus ther-
apy 
Excellent 
Chronic ra jection, will 
require retransplan-
tation 
Died with massive 
liver ischemia with-
out apparent vascu-
lar obstruction 
Follow-up developmental and psychometric 
testing has revealed normal developmental 
progression in the 4 pretransplantation "nor-
mal" children and developmental catch-up, 
though still delayed for age, in the pretrans-
plantation delayed child. 
Complications 
Hypertension was the most frequent post-
operative complication encountered. It oc-
curred to some degree in all but two of the 
patients. The hypertension generally resolved 
after 2-3 months. There have been two 
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Fig. 1. Patient growth curve. 
patients who were exceptions to this. Patient 
OT 192 has had late recurrence of hyperten-
sion, and patient OT 206 has had persistence 
of postoperative hypertension. 
Pulmonary edema in the immediate postop-
erative period occurred with some frequency 
early in the series. More conservative fluid 
management in the patients transplanted in 
the latter half of the series has decreased this 
problem considerably. 
Renal dysfunction with low fractional uri-
nary sodium excretion occurred in a number 
?f pa tients and was either hepatorenal or Cy A 
Induced. Normalization of renal function 
occurred either with time and a good function-
ing graft or with decreases of CyA dosing. 
Two patients required a short period of dis-
continuation of CyA with a switch to azothia-
prine until renal function recovered (2 days). 
Reinstitution of CyA at a lower dose did not 
cause recurrence of renal dysfunction. 
Postoperative fever occurred in 18/23 
1295 
patients. Etiology was viral infection in 2 
cases (EBV in 1 patient and CMV in anoth-
er), bacterial infection in 4 cases (cholangitis 
in I patient, peri tom tis in 1 patient, phlebitis 
in 1 patient, and biliary abscess in 1 patient), 
fungal in I case (candida liver abscess), and 
nocardia in 1 case (pulmonary nocardosis). Of 
the remaining 10 patients, fever was asso-
ciated with biopsy proven rejection in 4 
patients and presumed rejection in 2 patients. 
Of the 4 patients with unexplained fever, one 
later developed rejection, while in 3 patients 
fever resqlved without explanation. Two of the 
patients in the series (OT 213 and 229) had 
infection and rejection. The former had CMV 
and mild rejection, while the latter had pul-
monary nocardosis and severe rejection. 
A number of single complications, includ-
ing recurrent laryngeal nerve injury, phrenic 
nerve injury on the right, obstruction of the 
portal vein at the anastomosis site requiring 
reoperation and correction, and peroneal 
palsy with foot drop, occurred. 
Deaths in the series were clearly rejection-
mediated in only 1 patient. One patient had 
sudden liver failure with marked transami-
nase rise at 1 week posttransplantation. Post-
mortem evaluation revealed an ischemic liver 
despite patent vascular anastomoses. One 
patient thought to have a patent portal vein by 
preoperative sonography had a completely 
thrombosed portal vein at the time of surgery 
and hence was unable to receive a surgically 
acceptable transplant. Another patient had an 
absent superior vena cava (SVC) with upper 
body venous drainage ultimately returning to 
the heart by way of the inferior vena cava 
(lVC). That patient died intraoperatively at 
the time of cross clamping of the lVe. One 
patient had a biliary abscess that led to his 
demise, while another patient died due to 
overwhelming sepsis. Finally, one patient died 
following a third attempt at transplantation 
due to an intracranial hemorrhage. 
DISCUSSION 
Review of the patient data has shed light on 
a number of points. Two presuppositions: (I) 
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that patients with biliary atresia have a poorer 
outcome at liver transplantation versus chil-
dren with other indications for liver transplan-
tation owing to the greater difficulty of sur-
gery in the child with previous abdomenal 
surgery (i.e., portoenterostomy), and (2) that 
the more gravely ill patients do less well than 
the more stable patients, did not hold true. 
Failure of these presuppositions to hold in this 
series may be merely a function of its small 
numbers, but, alternatively, it may be due to 
the coming of age of the actual surgical proce-
dure of liver transplantation, while the immu-
nologic barrier remains the major problem to 
be surmounted. The rapid normalization of 
severe metabolic derangements following suc-
cessful transplantation have allowed the sick-
est of patients (OT 202. 237) to come back 
from the brink of death. while other patients 
(OT 2 I 6,232) in stable condition at the time 
of transplantation have gone on to their dem-
ise following rejection or apparent rejection of 
the transplanted organ. 
The patient data to date support the use of 
OL T in pediatric patients. Essentially since its 
inception, the use of 0 L T in children has been 
controversial. Starzl et al. have felt that chil-
dren are excellent liver transplantation recip-
ients, and point to their better survival statis-
tics compared to adults. Caine et al. have been 
reluctant to perform transplantation in the 
pediatric age group for several reasons, the 
foremost being the known long-term toxic side 
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effects of immunosuppressive drugs, espe-
cially corticosteroids which causes growth 
retardation and associated Cushingoid fea-
tures. 
The description by Borel et al. il of a fungus 
extract, CyA, which is a powerful immuno-
suppressant and which was later shown to be 
an effective anti rejection agent, either by 
itselfl.j or in conjunction with low-dose ste-
roids,ll held the promise of eliminating the 
major toxic side effects of previous immuno-
suppressive regimens. Our data to date sup-
port the value of CyA in reducing the toxic 
side effects of previous immunosuppressive 
therapy. Children on the regimen of low-dose 
steroids and CyA not only show improved 
survival but attain normalization of growth 
velocity posttransplantation. Whether other 
delayed or more subtle toxic effects of CyA 
and low-dose steroids in children will later 
occur will have to await longer follow-up 
time. 
ADDENDUM 
Since submitting this article five more 
months of follow-up time have passed. The 
two patients suffering from chronic rejection 
(OT 214, 229) have succumbed to complica-
tions of their rejection or therapeutic interven-
tion taken in an attempt to control rejection. 
The remaining 14 patients are continuing to 
do well. 
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